Historical cl News Stories

Colgate-Palmolive's Strategic Initiatives and Financial Performance in 2026

An overview of Colgate-Palmolive's recent strategic moves and financial results.

Colgate-Palmolive's Recent Developments and Stock Performance

An overview of Colgate-Palmolive's recent financial activities and stock trends.

India Profit Dip Hits Colgate; Institutions Buy CL

Colgate‑Palmolive saw a modest profit decline in its India unit for Q4, while several institutional investors added CL shares. The week’s developments were concrete but not disruptive, leaving Colgate’s S&P 500-listed stock largely steady.

Colgate Q1 Beat: Dividends, SGPP Cuts Pet Strength

Colgate‑Palmolive’s Q1 beat lifted CL stock as the company raised its dividend, outlined SGPP cost-savings targets and highlighted strength in Hill’s Pet Nutrition—offset by North America weakness and elevated input costs.

Colgate Q1 Boost, Margin Pressure & SGPP Plan

Colgate‑Palmolive’s Q1 results showed solid top‑line growth and strong cash flow, but near‑term margins face pressure as the company expands a cost‑reduction program. Analysts responded with cautious optimism; execution of the program and higher marketing spend are key for CL stock performance.

Colgate Q1 Beat, SGPP Boost Savings; Margins Tight

Colgate-Palmolive beat Q1 expectations as international demand drove organic sales growth. Margins remain pressured by raw-material and logistics inflation, prompting an expanded Strategic Growth & Productivity Program (SGPP). Analysts adjusted targets while institutional buyers added shares. The company maintained full-year guidance and outlined cost-saving measures aimed at restoring margin momentum.

Colgate-Palmolive Downgrade, Insider Sales Q1 Now!

TD Cowen's March 31 downgrade of Colgate‑Palmolive and recent insider share sales have shifted near-term sentiment for CL stock. With Q1 earnings in focus, investors should watch organic growth, gross margins and pet-nutrition momentum to assess whether the company can counter short-term headwinds in oral hygiene and consumer pricing.

Colgate Lawsuits Spotlight Kids' Mouth Rinse Risk.

A recent federal ruling allows class-action suits over Colgate’s children’s mouth rinses to proceed, heightening legal and reputational risk for CL even as the company reports solid fundamentals.

Colgate Stock Slides After Insider Sell-Off

Colgate‑Palmolive (CL) faced a short-term pullback after a large insider sale and renewed investor focus on leverage, even as Morgan Stanley keeps the stock as a top pick. Recent competitor moves toward hygiene categories further validate Colgate’s positioning. This article breaks down the events, their direct impact on CL, and the practical metrics investors should watch next.

Colgate Boosts Dividend, Unveils 2030 Growth Plan.

Colgate‑Palmolive raised its quarterly payout, added a scientific board member, and detailed a 2030 strategic roadmap after solid Q4 results and record free cash flow—moves that have buoyed CL stock and drawn bullish analyst attention.

Colgate Hikes Dividend; Board, Segment Shakeup Q2.

Colgate‑Palmolive raised its quarterly payout, refreshed its board with a high-profile healthcare executive, and reorganized regional reporting—moves that signal financial stability and strategic repositioning. Short-term stock weakness contrasts with analyst upgrades and DCF-based valuation upside, making CL noteworthy for income and long-term growth investors.

Colgate Surge: Q3 Stability, Innovation Focus Now!

Colgate-Palmolive (CL) drew heightened investor attention this week after a spike in media coverage and steady Q3 financials. This article summarizes the concrete events — elevated news flow, Q3 segment results, and strategic innovation moves in oral care — and explains why these developments matter for CL stock.

Colgate's $919M Hit, Toothpaste Share & Pet Push!!

Colgate‑Palmolive reported a $919M pre-tax impairment in its Skin Health segment while oral-care volumes dipped despite price increases. Regulatory settlements over children’s toothpaste packaging and continued strength in toothpaste share and Hill’s pet nutrition expansion shape near-term pressures and long-term diversification.

Colgate Gains: WHO Tie‑Up and Morgan Stanley Lift!

Colgate‑Palmolive received a meaningful boost after announcing a multi‑year collaboration with the WHO Foundation and securing renewed analyst support from Morgan Stanley. These concrete developments strengthened the stock’s defensive narrative, produced a near‑term share uptick, and provided measurable analyst upside—while leaving the immediate earnings profile largely unchanged.

Colgate’s WHO Deal Fuels CL Stock Surge to $93 Now

Colgate‑Palmolive’s new WHO Foundation partnership and subsequent analyst upgrades lifted CL shares roughly 5–6% as firms like JPMorgan and BNP raised price targets to about $93.

CL Stock Strengthens After WHO Oral-Health Tie-up.

Colgate‑Palmolive (CL) showed resilient share performance and rising technical momentum this week after announcing a WHO Foundation partnership. Improved relative strength, modest analyst upside and solid dividend metrics frame a cautious but constructive view for investors.